Applying radiofrequency (RF) energy to the left atrial appendage (LAA) in patients with residual leak after Watchman (Boston Scientific) implantation might be a viable way to eliminate peridevice ...

Left atrial appendage (LAA) closure with the new-generation Watchman FLX device (Boston Scientific) provides a high rate of effective closure with few early adverse events, according to results of ...

In-hospital safety and procedural outcomes for percutaneous left atrial appendage (LAA) closure are substantially better with the Watchman FLX device than with its predecessor, new research shows.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A next-generation left atrial appendage closure device ...

(RTTNews) - Medical technology company Boston Scientific Corp. (BSX) announced Tuesday that it has received U.S. Food and Drug Administration approval for expanded labeling of WATCHMAN FLX Left Atrial ...

Boston Scientific suspended the sales of its second-generation Watchman FLX in Europe because of embolism concerns. Patients who received the device showed unexpectedly high embolic rates. The ...

The Heart Institute of East Texas proudly introduces the latest advancement in cardiac care with the implementation of the Watchman Flx Pro Left Atrial Appendage Occluder implantation technology. This ...

Expanding its Interventional Cardiology (IC) suite, Boston Scientific CorporationBSX recently announced receipt of the CE Mark for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) device. At the ...